Metabolic syndrome: A multiplex cardiovascular risk factor

Journal of Clinical Endocrinology and Metabolism

Volumn 92, Issue 2, 2007, Pages 399-404

  Grundy, Scott M ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

BLEEDING; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL EXAMINATION; CLINICAL PRACTICE; CORONARY ARTERY ATHEROSCLEROSIS; DIAGNOSTIC VALUE; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; HEALTH CARE COST; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; ISCHEMIC HEART DISEASE; LIFESTYLE; LIFESTYLE MODIFICATION; LIPOPROTEIN BLOOD LEVEL; METABOLIC SYNDROME X; OBESITY; POLYPHARMACY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SMOKING CESSATION; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

EID: 33846970555     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2006-0513     Document Type: Article

References (29)

1. Alberti KG, Zimmet PZ 1998 Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15:539-553
2. 2002 Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Final Report. Circulation 106:3143-3421
3. Einhorn D 2003 ACE position statement on insulin resistance syndrome. Endocr Pract 9:237-252
4. Balkau B, Charles MA 1999 Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 16:442-443
5. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith Jr SC, Spertus JA, Costa F 2005 Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112:2735-2752
6. Alberti KGMM, Zimmet P, Shaw J 2005 IDF Epidemiology Task Force Consensus Group. Lancet 66:1059-1062
7. Kahn R, Buse J, Ferrannini E, Stern M 2005 The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 28:2289-2304
8. Reaven GM 2006 The metabolic syndrome: is this diagnosis necessary? Am J Clin Nutr 83:1237-1247
9. Garg A 2004 Acquired and inherited lipodystrophies. N Engl J Med 350:1220-1234
10. Reaven GM 1988 Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37:1595-1607
11. Reaven GM 1993 Role of insulin resistance in human disease (syndrome X): an expanded definition. Annu Rev Med 44:121-131
12. Eckel RH, Grundy SM, Zimmet PZ 2005 The metabolic syndrome. Lancet 365:1415-1428
13. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB 2003 The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 163:427-436
14. Yki-Jarvinen H 2005 Fat in the liver and insulin resistance. Ann Med 37:347-356
15. Scherer PE 2006 Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes 55:1537-1545
16. Stern MP, Williams K, Gonzalez-Villalpando C, Hunt KJ, Haffner SM 2004 Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care 27:2676-2681
17. Sundstrom J, Riserus U, Byberg L, Zethelius B, Lithell H, Lind L 2006 Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality: prospective, population based cohort study. BMJ 332:878-882
18. Stevens R, Kothari V, Adler AI, Stratten IM, Holman RR. UKPDS Group 2001 The UKPDS risk engine: a model for the risk of coronary heart disease in type 2 diabetes. Clin Sci (Lond) 101:671-679
19. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM 2006 Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 295:1549-1555
20. Ford ES, Giles WH, Dietz WH 2002 Prevalence of the metabolic syndrome among US adults. Findings from the Third National Health and Nutrition Survey. JAMA 287:356-359
21. Wooley SC, Garnern DM 1991 Obesity treatment: the high cost of false hope. J Am Diet Assoc 191:1248-1251
22. 1998 Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Arch Intern Med 158:1855-1867
23. Knowler WC, Barrett Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM, Diabetes Prevention Program Research Group 2002 Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403
24. Deedwania P, Barter P, Carmena R, Fruchart JC, Grundy SM, Haffner S, Kastelein JJ, LaRosa JC, Schachner H, Shepherd J, Waters DD; Treating to New Targets Investigators 2006 Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet 368:919-928
25. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr J, Jones DW, Materson BJ, Oparil S, Wright Jr JT, Roccella EJ, National Heart Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, National High Blood Pressure Education Program Coordinating Committee 2003 The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 289:2560-2572
26. American Diabetes Association 2006 Summary of revisions for the 2006 Clinical Practice Recommendations. Diabetes Care 29(Suppl 1):S3
27. Grundy SM 2006 Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. Nat Rev Drug Discov 5:295-309
28. . Grundy SM, Cleeman JI, Merz CN, Brewer Jr HB, Clark LT, Hunninghake DB, Pasternak RC, Smith Jr SC, Stone NJ 2004 National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110:227-239
29. Jandeleit-Dahm KA, Tikellis C, Reid CM, Johnston CI, Cooper ME 2005 Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens 23:463-473